Marketed therapeutic antibodies compendium
Open Access
- 1 May 2012
- journal article
- Published by Taylor & Francis in mAbs
- Vol. 4 (3) , 413-415
Abstract
Therapeutic monoclonal antibodies (mAbs) are currently being approved for marketing in Europe and the United States, as well as other countries, on a regular basis. As more mAbs become available to...Keywords
This publication has 9 references indexed in Scilit:
- The birth pangs of monoclonal antibody therapeuticsmAbs, 2012
- Which are the antibodies to watch in 2012?mAbs, 2012
- Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell LymphomaJournal of Clinical Oncology, 2010
- Antibody immunosuppressive therapy in solid-organ transplantmAbs, 2010
- Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originmAbs, 2009
- Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised studyThe Lancet, 2002
- Delaying approval of a critical drug: Safety, efficacy, economics, compassionJournal of Medical Humanities, 1994
- Expression of spleen cell immunoglobulin phenotype in hybrids with myeloma cell linesSomatic Cell and Molecular Genetics, 1981
- A better cell line for making hybridomas secreting specific antibodiesNature, 1978